Tofa expansion jobs on HOLD -





What became of the tofa contract jobs? I thought those people were hired early July.

I have been a "finalist" for the contract RA contact job since June. This means I am one of the final two being considered for the contract. Meet and Greets with the "client" were to have been the week of July 9th. They have been on hold since then. Publicis just keeps stringing us along. They won't even say who the contract is with, or what the drug is but we all know. I just hope it gets approved this week. I need a job.
 








I have been a "finalist" for the contract RA contact job since June. This means I am one of the final two being considered for the contract. Meet and Greets with the "client" were to have been the week of July 9th. They have been on hold since then. Publicis just keeps stringing us along. They won't even say who the contract is with, or what the drug is but we all know. I just hope it gets approved this week. I need a job.

Sorry to burst your bubble but even it does get approved, you still have to beat out the other person for the job. Keep looking elsewhere, you probably will be waiting awhile
 












The U.S. Food and Drug Administration extended by three months its review of Pfizer Inc's (PFE: 23.75, -0.16, -0.67%) experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline.

In July, Pfizer disclosed that the FDA sought a "routine" analysis of clinical trial data for the drug that could delay a decision by three months or more beyond the agency's Aug. 21
deadline.

If approved, the pill could offer a more convenient alternative to Abbott Laboratories Inc's (ABT: 65.58, -0.15, -0.22%) $8 billion-a-year injectable medication Humira. The FDA now views the additional analysis as a major amendment to Pfizer's application for approval, and set a new Nov. 21 deadline for reviewing the drug, the company said on Tuesday. It did not give more details of the data analysis it provided.

Pfizer said it still believes trial results favor the drug's use, and is working with the FDA, as well as regulators in Europe, Japan and other countries, to bring it to market. Rheumatoid arthritis, a chronic inflammatory autoimmune disease, affects about 1.6 million Americans and 23.7 million people worldwide, the company said.

Tofacitinib blocks signals that activate immune and inflammatory responses in the body, and is the first in a new class of drugs called Janus kinase (JAK) inhibitors. A panel of outside advisers to the FDA recommended the agency approve the drug during a May meeting, though many said it should be used only after patients had tried other treatments. Safety concerns included possible infections, such
as pneumonia, or malignancies. Wall Street analysts estimate that tofacitinib could reap up to $3 billion in annual sales if approved.

Pfizer shares rose 2 cents to $23.91 in premarket trading.


Read more: http://www.foxbusiness.com/industri...o-review-pfizer-arthritis-drug/#ixzz24CNgwhT2
 








Will they hire recently posted positions?

Yes, Pfizer will still hire all Tofa expansion positions. Those Reps will be trained on other important drugs (Pristiq, Toviaz, Chantix, PVC and Prem. orals) The company feels these drugs will eventually be blockbuster type products. In 2019 after Tofa is approved, you will begin selling it as a 3rd line agent.

Rest assured, you will be ok.
 




Yes, Pfizer will still hire all Tofa expansion positions. Those Reps will be trained on other important drugs (Pristiq, Toviaz, Chantix, PVC and Prem. orals) The company feels these drugs will eventually be blockbuster type products. In 2019 after Tofa is approved, you will begin selling it as a 3rd line agent.

Rest assured, you will be ok.

I heard TOFA would be approved as a 4th agent. Must fail 3 TNFs to get it.
 








Similar threads

Replies
3
Views
406
Pfizer
anonymous
Replies
5
Views
2K
Pfizer
Anonymous
Replies
6
Views
2K
Pfizer
Anonymous